Clinical trials
Relapsed B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06101381RecruitingPhase 1/Phase 2
Car-T cell therapy for relapsed or refractory leukemia and lymphoma
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
Campinas, São PauloAges 3–70 - NCT06104553RecruitingPhase 1/Phase 2
Study of SHR-A1912 with other treatments for B-cell lymphoma
This trial tests a new combination therapy for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to see if adding SHR-A1912 to other treatments can help shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06120166RecruitingEarly Phase 1
Metabolically armed CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Philadelphia, PennsylvaniaAges birth–18 years - NCT06180174RecruitingPhase 1
CD19-targeted CAR-T cells for relapsed B-cell lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06189391RecruitingPhase 1
Testing CN201 for people with relapsed or refractory B-cell lymphoma
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT06313957RecruitingPhase 1
Study of LUCAR-20SP for relapsed B-cell lymphoma
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07308132RecruitingPhase 1
Study of a new drug for certain lymphomas
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
ClaytonAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+ - NCT06392477RecruitingPhase 1
Testing a new drug for relapsed B-cell lymphoma
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Camperdown, New South WalesAges 18 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06479356RecruitingPhase 2
CAR T-cell therapy for relapsed large B-cell lymphoma
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06484920RecruitingPhase 2
Pembrolizumab and ATRA for relapsed lymphoma
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Indianapolis, IndianaAges 18 years+ - NCT05098613RecruitingPhase 1
Testing a new immune cell therapy for relapsed B-cell lymphoma
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Aurora, ColoradoAges 16 years+
Hear when a new Relapsed B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 151 recruiting relapsed b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- B-Cell Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
- B-cell Non-Hodgkin Lymphoma (B-NHL)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.